کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
10027993 | 1591923 | 2005 | 10 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125Â mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری
ایمنی شناسی و میکروب شناسی
میکروبیولوژی و بیوتکنولوژی کاربردی
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125Â mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125Â mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains](/preview/png/10027993.png)
چکیده انگلیسی
Community-acquired pneumonia (CAP) is a common respiratory illness, frequently caused by Streptococcus pneumoniae. The prevalence of S. pneumoniae resistance to common antimicrobials has increased over recent years. A new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) has been developed, designed to combat infections caused by S. pneumoniae, including penicillin-resistant (PRSP, penicillin minimum inhibitory concentrations (MICs) â¥2 mg/l) isolates, and those with elevated amoxicillin/clavulanic acid MICs, while maintaining coverage of β-lactamase-producing pathogens. A pooled efficacy analysis of four randomized (1:1) and one non-comparative clinical trials of amoxicillin/clavulanate, 2000/125 mg, given twice daily, was conducted in adult patients with CAP. Comparator agents were conventional amoxicillin/clavulanate formulations. At follow-up (days 16-39), efficacy (eradication of the initial pathogen or clinical cure in patients for whom no repeat culture was performed) in patients with S. pneumoniae infection was 92.3% (274/297) for amoxicillin/clavulanate, 2000/125 mg and 85.2% (46/54) for comparators (P = 0.11). Twenty-four of 25 PRSP-infected patients receiving amoxicillin/clavulanate, 2000/125 mg were treated successfully. Both amoxicillin/clavulanate, 2000/125 mg and comparators were well tolerated, with few patients withdrawing from the studies.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: International Journal of Antimicrobial Agents - Volume 25, Issue 2, February 2005, Pages 110-119
Journal: International Journal of Antimicrobial Agents - Volume 25, Issue 2, February 2005, Pages 110-119
نویسندگان
Thomas M. File, Javier Garau, Michael R. Jacobs, Brian Wynne, Monique Twynholm, Elchonon Berkowitz,